T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities

T-cell-engaging antibodies or T-cell engagers (TCEs) can connect a patient's cytotoxic T cells with cancer cells, leading to potent redirected lysis. Until very recently, only one TCE was approved, the CD19/CD3-bispecific blinatumomab. Many new TCEs in late-stage clinical development target var...

Descripción completa

Detalles Bibliográficos
Autores principales: Baeuerle, Patrick A., Wesche, Holger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
INNOVATIVE AGENTS AND TREATMENT MODALITIES: Edited by Ahmad Awada and Steven T. Rosen
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9415207/
https://www.ncbi.nlm.nih.gov/pubmed/35880455
http://dx.doi.org/10.1097/CCO.0000000000000869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9415207/
https://www.ncbi.nlm.nih.gov/pubmed/35880455
http://dx.doi.org/10.1097/CCO.0000000000000869

Ejemplares similares